Online inquiry

IVTScrip™ mRNA-Anti-ERBB2&TNFRSF9, PRS-343(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ13459MR)

This product GTTS-WQ13459MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets ERBB2&TNFRSF9 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Chimeric
RefSeq NM_001005862.3; NM_001561.6
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2064; 3604
UniProt ID P04626; Q07011
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ERBB2&TNFRSF9, PRS-343(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ13459MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ11467MR IVTScrip™ mRNA-Anti-ERBB3, MEHD7945A(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MEHD7945A
GTTS-WQ287MR IVTScrip™ mRNA-Anti-CD37, 177lu-DOTA-HH1(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA 177lu-DOTA-HH1
GTTS-WQ15354MR IVTScrip™ mRNA-Anti-ENG, TRC-105(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA TRC-105
GTTS-WQ1544MR IVTScrip™ mRNA-Anti-MSTN, ACE-031(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ACE-031
GTTS-WQ14005MR IVTScrip™ mRNA-Anti-IL33, REGN-3500(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA REGN-3500
GTTS-WQ13834MR IVTScrip™ mRNA-Anti-S, REGN-10987(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA REGN-10987
GTTS-WQ4843MR IVTScrip™ mRNA-Anti-SDC1, BT-062(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA BT-062
GTTS-WQ4669MR IVTScrip™ mRNA-Anti-MSTN, BMS-986089(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA BMS-986089
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW